About Dr. Sridhar P S
Prof. Dr. Sridhar Papaiah Susheela is a highly acclaimed Radiation Oncologist in India. He is a foremost expert in cutting-edge radiation technologies. Dr. Sridhar is particularly renowned for his mastery of Cyberknife radiosurgery, having trained at Stanford University. His expertise extends to IMRT, IGRT, SBRT, TomoTherapy, Brachytherapy, and PET CT-based planning. Committed to advancing oncology, he holds leadership positions in several professional societies, has over 135 publications, and actively incorporates genomics, radiogenomics, and AI into providing personalised, high-precision cancer care. Also, he is one of the best cancer doctor in Bangalore.
- MBBS – Govt. Medical College, Mysore University (1996)
- MD (Radiotherapy and Oncology) – Institute Of Medical Sciences, Banaras Hindu University (BHU), Varanasi (2002)
- DNB (Radiotherapy and Oncology) – National Board of Examination, All India Institute of Medical Sciences (AIIMS), New Delhi (2004)
- Cyberknife Training (Whole Body Stereotactic Robotic Radiosurgery) – Stanford University, USA
- Awarded Travelling Fellowship – Uttar Pradesh Association of Radiation Oncologists of India (UP AROI) (2001)
- Awarded Best Association of Radiation Oncologists of India (AROI) Fellowship (2007-2008)
- Awarded International Travelling Fellowship of Radiation Oncologists of India (AROI) (2010 – 2011)
- Awarded Commonwealth Scholarship for Cancer Research from India to the United Kingdom (2005-2006)
- Brain Tumours (Benign & Malignant)
- Head & Neck Cancers
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
- Liver Cancer (Hepatobiliary)
- Spine Tumours
- Kidney Cancer
- Neurological Tumours
- Gynaecological Cancers (e.g., Cervical)
- Bladder Cancer
- Hodgkin’s Disease
- Chondrosarcoma
- Other Complex/Inoperable Tumours
- Radiation Oncology
- Cyberknife Robotic Radiosurgery
- Neuro-Oncology (Radiation focus)
- Functional Radiosurgery
- Precision Radiation Oncology
- Oncology Imaging (PET CT based Planning)
- Radiogenomics & Genomics in Oncology
- Cyberknife Robotic Radiosurgery
- Intensity Modulated Radiation Therapy (IMRT)
- Image-Guided Radiation Therapy (IGRT)
- Stereotactic Body Radiotherapy (SBRT)
- Stereotactic Radiosurgery (SRS)
- TomoTherapy
- Brachytherapy
- Hyperthermia
- Chemoradiotherapy (Concurrent Treatment)
- Immunoradiotherapy (Combination with Immunotherapy)
- PET CT Based Radiotherapy Planning
- Targeted Therapy (in conjunction with Radiotherapy)
- Lead Cyberknife Radiosurgery & Senior Consultant, Dept of Radiation Oncology: Apollo Hospitals, Bangalore (Present)
- Senior Consultant Radiation Oncology: Apollo Proton Cancer Centre, Chennai (Concurrent Role)
- Director Cyberknife & Clinical Head International, Senior Consultant Radiation Oncology: HealthCare Global Enterprises Ltd (HCG), Bangalore
- Consultant Radiation Oncology: Gokul Curie Centre of Oncology, MS Ramaiah Medical College, Bangalore
- Consultant Radiation Oncology: Curie Centre of Oncology, St. Johns Medical College, Bangalore
- Consultant Radiation Oncology: Manipal Hospital Bangalore
- Consultant Radiation Oncology: Kidwai Memorial Institute of Oncology, Bangalore
- Senior Resident Radiotherapy and Oncology: All India Institute of Medical Sciences (AIIMS), New Delhi
- Observer: Tata Memorial Center, Mumbai
- Senior/Junior Resident Radiotherapy and Oncology: Institute of Medical Sciences, Banaras Hindu University (BHU), Varanasi
- Clinical Lead Cyberknife: Apollo Hospitals, Bangalore
- Head of Cyberknife Academia (Previous Role Implied)
- President: Association of Radiation Oncologists of India (AROI) – Bengaluru Chapter
- Secretary: Neuro-Oncology Society, Bangalore
- Secretary: Indian Association of Hyperthermic Oncology and Medicine
- Joint Secretary: Bangalore Oncology Group (BOG)
- Joint Secretary: Association of Radiation Oncologists of India (AROI) (Past Role)
- Faculty and Mentor to junior oncologists (Implied)
- Reviewer for Oncology Journals (Implied)
- Advisory Role: GE Healthcare
- Pioneering expert in Cyberknife radiosurgery in India with Stanford training.
- Treated over 10,000 cancer patients, including over 3,000 with Cyberknife.
- Extensive experience (26+ years) in high-precision radiotherapy techniques.
- Authored over 135 publications in national and international journals.
- Holds significant leadership positions in major Indian oncology societies.
- Recipient of prestigious fellowships and the Commonwealth Scholarship.
- Actively involved in advancing the field through research (including Phase III trials) and adoption of new technologies (AI, Genomics).
- Commonwealth Scholarship for Cancer Research (India to UK) (2005-2006)
- Best Association of Radiation Oncologists of India (AROI) Fellowship (2007-2008)
- International Travelling Fellowship of Radiation Oncologists of India (AROI) (2010 – 2011)
- Travelling Fellowship, Uttar Pradesh Association of Radiation Oncologists of India (UP AROI) (2001)
- American Society of Therapeutic Radiation and Oncology (ASTRO)
- American Society of Clinical Oncology (ASCO)
- European Society of Medical Oncology (ESMO)
- Association of Radiation Oncologists of India (AROI)
- National Academy of Medical Sciences (MNAMS)
- Society of Neuro-Oncology (SON)
- Neuro-oncology Society of India
- Indian Association of Hyperthermic Oncology and Medicine
- Bangalore Oncology Group (BOG)
- “Dose Escalation Using Concurrent Chemoradiotherapy with Simultaneous Integrated Boost Using PET CT Planning in Locally Advanced Esophageal Cancer.” International Journal of Radiation Oncology, Biology, Physics (2022).
- “Recurrent squamous cell carcinoma of the skin treated with immunotherapy.” Journal of Cancer Research and Therapeutics (2022).
- “Fsrs By Cyberknife For Glomus Jugulare-Hcg India Experience.” Journal of Cancer Research & Therapeutics (2017).
- “Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.” The Lancet Oncology (2017).
- Past participation as investigator/co-investigator in Phase III trials for Non-Small Cell Lung Cancer (NSCLC), Glioblastoma, and Venous Thromboembolism (VTE) in Cancer Patients (2009-2010). Continues involvement in clinical research.
- Consultation Fee: To know Dr. Sridhar P S consultation fee, consult with our Cancer Rounds team.
- Treatment Costs: Costs for advanced radiation therapy vary based on the specific technique, number of sessions, tumour location/complexity, and hospital facility. Below are indicative estimates..
Treatment/Procedure for Cancer | Estimated Cost (INR) | Estimated Cost (USD) |
Cyberknife Radiosurgery (Course) | ₹ 5,00,000 – ₹ 10,00,000+ | $ 6,000 – $ 12,000+ |
Stereotactic Body Radio Therapy (SBRT) | ₹ 4,00,000 – ₹ 8,00,000+ | $ 4,800 – $ 9,600+ |
Intensity Modulated Radio Therapy (IMRT) | ₹ 2,50,000 – ₹ 5,00,000+ | $ 3,000 – $ 6,000+ |
Image Guided Radio Therapy (IGRT) | ₹ 3,00,000 – ₹ 6,00,000+ | $ 3,600 – $ 7,200+ |
TomoTherapy (Course) | ₹ 4,50,000 – ₹ 9,00,000+ | $ 5,400 – $ 10,800+ |
- Language Support: Cancer Rounds team can arrange for interpreters for other languages.
- Visa & Travel Assistance: Assistance with medical visa invitation letters, travel logistics, airport transfers, and accommodation can be facilitated by the Cancer Rounds team.
- Pre-treatment Virtual Consultations: Dr. Sridhar offers online consultations. International patients can utilize this service via Cancer Rounds team for initial assessments and treatment planning before travelling.
- Patient-Centred Care: Dr. Sridhar is known for his compassionate and friendly nature, creating a secure environment for patients. He is a keen listener, focusing on providing result-oriented treatments that enhance quality of life. He strongly believes in the importance of prevention and early cancer detection.
- Technology & Innovation: A pioneer in adopting the latest advancements, Dr. Sridhar excels in high-precision techniques like Cyberknife, SBRT, IMRT, IGRT, TomoTherapy, and PET-based planning. He actively integrates knowledge of genomics, radiogenomics, AI, and immunoradiotherapy to offer treatments on par with international standards, aiming for maximum tumour control with minimal side effects.